ABOS vs. ORGO, AURA, KALV, ETON, PRME, VALN, KRRO, ENGN, GLUE, and RGNX
Should you be buying Acumen Pharmaceuticals stock or one of its competitors? The main competitors of Acumen Pharmaceuticals include Organogenesis (ORGO), Aura Biosciences (AURA), KalVista Pharmaceuticals (KALV), Eton Pharmaceuticals (ETON), Prime Medicine (PRME), Valneva (VALN), Korro Bio (KRRO), enGene (ENGN), Monte Rosa Therapeutics (GLUE), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.
Acumen Pharmaceuticals vs.
Acumen Pharmaceuticals (NASDAQ:ABOS) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, community ranking, dividends, risk, institutional ownership, media sentiment and analyst recommendations.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Acumen Pharmaceuticals' return on equity.
Organogenesis has higher revenue and earnings than Acumen Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Acumen Pharmaceuticals currently has a consensus price target of $9.33, suggesting a potential upside of 472.60%. Organogenesis has a consensus price target of $5.00, suggesting a potential upside of 43.06%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Organogenesis.
71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 7.1% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 36.9% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Organogenesis received 72 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Acumen Pharmaceuticals an outperform vote while only 66.44% of users gave Organogenesis an outperform vote.
In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Acumen Pharmaceuticals and 2 mentions for Organogenesis. Acumen Pharmaceuticals' average media sentiment score of 0.83 beat Organogenesis' score of 0.33 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.
Acumen Pharmaceuticals has a beta of 0.02, suggesting that its share price is 98% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500.
Summary
Acumen Pharmaceuticals beats Organogenesis on 9 of the 17 factors compared between the two stocks.
Get Acumen Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acumen Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ABOS) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ABOS Stock Alerts